Characteristics of patients who received EBV-specific T cells for therapy for acute PTLD after allo-SCT
| Patient . | Age, y, sex . | Primary disease . | Transplant donor . | Time of transplantation* . | Time of diagnosis of PTLD* . | Time of RI* . | Rituximab, d* . | Cidofovir, d* . | Symptoms at time of T-cell transfer . | PTLD response . | Outcome, d* . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 24, F | AML | MMR | −62 | −5 | −5 | −5, −1, 5, 12 | −5, −2, 5 | Lymphadenopathy | CR | Alive & well (657) |
| 2 | 19, F | SAA | MU | −47 | −6 | −6 | −5, 0 | −5, 9 | Lymphadenopathy, tonsillitis, fever | CR | Alive & well (643) |
| 3 | 24, M | SAA | MMR | −63 | −6 | −6 | −6, −3 | −6, 2, 9 | Lymphadenopathy, fever | CR | Died (96), lung failure |
| 4 | 36, M | T-NHL | MMR | −71 | −5 | −3 | −3, 0 | −19,† −12, −3, −1 | Lymphadenopathy, fever, MOF‡ | NR | Died (1), MOF |
| 5 | 44, M | t-AML, after immunocytoma | MMR | −93 | −15 | −19† | −14, −8, 0 | −22,† 0, 3, 7, 10 | Lymphadenopathy, fever, MOF‡ | PD | Died (11), MOF |
| 6 | 46, M | Recurrent AML | MMR | −81 | −9 | −9 | −9, −7, −2, 4 | −9, −6, −1 | Lymphadenopathy, fever, MOF‡ | PD | Died (7), MOF |
| Patient . | Age, y, sex . | Primary disease . | Transplant donor . | Time of transplantation* . | Time of diagnosis of PTLD* . | Time of RI* . | Rituximab, d* . | Cidofovir, d* . | Symptoms at time of T-cell transfer . | PTLD response . | Outcome, d* . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 24, F | AML | MMR | −62 | −5 | −5 | −5, −1, 5, 12 | −5, −2, 5 | Lymphadenopathy | CR | Alive & well (657) |
| 2 | 19, F | SAA | MU | −47 | −6 | −6 | −5, 0 | −5, 9 | Lymphadenopathy, tonsillitis, fever | CR | Alive & well (643) |
| 3 | 24, M | SAA | MMR | −63 | −6 | −6 | −6, −3 | −6, 2, 9 | Lymphadenopathy, fever | CR | Died (96), lung failure |
| 4 | 36, M | T-NHL | MMR | −71 | −5 | −3 | −3, 0 | −19,† −12, −3, −1 | Lymphadenopathy, fever, MOF‡ | NR | Died (1), MOF |
| 5 | 44, M | t-AML, after immunocytoma | MMR | −93 | −15 | −19† | −14, −8, 0 | −22,† 0, 3, 7, 10 | Lymphadenopathy, fever, MOF‡ | PD | Died (11), MOF |
| 6 | 46, M | Recurrent AML | MMR | −81 | −9 | −9 | −9, −7, −2, 4 | −9, −6, −1 | Lymphadenopathy, fever, MOF‡ | PD | Died (7), MOF |
RI indicates reduction in immunosuppression; AML, acute myeloid leukemia; SAA, severe aplastic anemia; T-NHL, non-Hodgkin lymphoma of T-cell type; t-AML, treatment-related AML; MMR, HLA-haploidentical mismatched related donor; MU, matched unrelated donor; CR, complete remission; NR, no response assessable; PD, progressive disease; and MOF, multiorgan failure.
Times are indicated in days relative to adoptive transfer of EBV-specific T cells (day 0).
For patients 4 and 5, antiviral treatment was initiated on days −19 and −22, respectively, after diagnosis of lytic EBV infection.
Additional symptoms of patient 4 at the time of T-cell transfer included pneumonitis, hepatitis, pericarditis, hemorrhagic cystitis, and consecutive renal, respiratory, liver, and cardiac failures. Additional symptoms of patient 5 included pneumonitis with pleural effusion, hepatitis, and consecutive liver, respiratory, and hemodynamic failures. Additional symptoms of patient 6 were pneumonitis with pleural effusion, hepatitis, and consecutive respiratory, liver, renal, and hemodynamic failures. Leukemic spread of lymphoma cells was observed in patients 4 and 5 at the time of T-cell transfer.